Petros Pharmaceuticals, Inc. (PTPI) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Los analistas estiman Beneficio por acción (EPS) de $-53.25 y ingresos de $0.01B para el próximo año fiscal.
Historial de Beneficio por acción (EPS): 2024: real $-0.02 vs est $-53.25 (superó +100%). Precisión del analista: 0%.
